Knee Osteoarthritis Treatments Explained Using PRP Therapy

Understand PRP therapy for knee osteoarthritis and its role in managing symptoms for those suffering from knee joint degeneration.

Abstract

In this educational post, I present a clear, first-person walkthrough of how and why I use platelet-rich plasma (PRP) for patients with symptomatic knee osteoarthritis (OA), alongside integrative chiropractic care. Drawing from current, high-quality research and my clinical observations in a multidisciplinary setting, I explain what PRP is, how it works at the tissue and cellular levels, why it often outperforms corticosteroids and hyaluronic acid injections for pain and function, and where it appears to be chondroprotective. I outline selection criteria, preparation standards, ultrasound-guided injection protocols, and comprehensive rehabilitation including spinal and lower kinetic chain adjustments, myofascial therapies, neuromuscular retraining, and anti-inflammatory nutrition. I also discuss safety, contraindications, adjuncts such as exercise, weight optimization, sleep, and stress modulation, and how to monitor outcomes over time using validated measures. Throughout, I highlight the rationale for each choice so that patients and clinicians can understand the full, integrative pathway from assessment to recovery.

Why I Integrate PRP for Symptomatic Knee Osteoarthritis

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I regularly evaluate active adults and older patients with symptomatic knee osteoarthritis who are seeking durable pain relief and improved function without relying solely on medication or invasive procedures. Over years of practice, I have seen that integrating platelet-rich plasma with evidence-based chiropractic care and functional rehabilitation can meaningfully improve outcomes.

• PRP is an autologous orthobiologic—we concentrate a patient’s own platelets and inject them into the symptomatic joint to modulate inflammation and support tissue repair pathways.
• Comparative trials increasingly show PRP provides greater and longer-lasting improvements in pain and function than corticosteroids or hyaluronic acid alone in mild-to-moderate knee OA.
• Early data suggest PRP may be chondroprotective, potentially slowing degenerative changes when appropriately prepared and delivered.

In my clinical experience, when PRP is combined with precise biomechanical correction—including lumbar-pelvic, hip, knee, and foot-ankle alignment—plus progressive loading and lifestyle medicine, patients not only feel better but also move better, sustaining gains over time (Jimenez, n.d.-a; Jimenez, n.d.-b).

What Platelet-Rich Plasma Is and Why It Matters

PRP is a concentrate of a patient’s platelets obtained by centrifuging whole blood to separate plasma layers. Platelets contain a dense cargo of growth factors and bioactive peptides that influence joint homeostasis:

• Key mediators: Platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-?), vascular endothelial growth factor (VEGF), insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF).
• Mechanisms in OA:

• • Modulation of synovial inflammation via shifts in cytokine balance (e.g., decreasing IL-1?, TNF-? signaling and MMP expression) leading to reduced nociception and effusion.
  • Support for chondrocyte anabolism, enhancing extracellular matrix synthesis (e.g., type II collagen, aggrecan) and dampening catabolic enzymes.
  • Improvement in intra-articular environment by reducing oxidative stress and possibly improving synovial fluid viscosity through hyaluronan synthesis pathways.
  • Promotion of angiomodulation in periarticular tissues aiding repair without provoking pathological neovascularization when leukocytes are controlled.

These effects align with the multidimensional pathology of OA, which includes cartilage wear, synovitis, subchondral bone remodeling, and neurosensory sensitization. By targeting multiple nodes, PRP often yields more durable relief than single-pathway injectables.

Evidence Summary: PRP vs Corticosteroids and Hyaluronic Acid

In recent years, head-to-head trials and systematic reviews have clarified relative performance:

• Corticosteroids provide rapid but short-lived symptom relief (often peaking by 2–4 weeks), with diminishing benefits by 8–12 weeks and concerns about repeated dosing potentially accelerating cartilage loss through catabolic actions (e.g., upregulation of MMPs and suppression of chondrocyte proliferation) (Bannuru et al., 2019; Kolasinski et al., 2020).
• Hyaluronic acid (HA) can improve viscoelasticity and has modest symptom benefit, often peaking around 8–12 weeks with variable durability (Bannuru et al., 2015).
• PRP generally shows superior pain and function outcomes at mid-term follow-up (3–12 months) compared to both corticosteroids and HA in mild-to-moderate OA, with growing evidence for structural benefits or slowed progression in select cohorts (Xing et al., 2021; Di Martino et al., 2019; Bennell et al., 2021).

Why PRP often outperforms:

• It addresses the inflammatory microenvironment and stimulates repair rather than simply masking inflammation (steroids) or providing lubrication (HA).
• Properly prepared PRP can deliver a balanced profile of growth factors that favor anabolism and homeostasis in the joint.

My clinical observations mirror these findings: patients receiving PRP within an integrated program demonstrate sustained improvements in pain scores, walking tolerance, stair negotiation, and sport-specific tasks, often beyond 6–12 months, particularly when kinetic chain mechanics are corrected (Jimenez, n.d.-a; Jimenez, n.d.-b).

Chondroprotection: What Current Research Suggests

The term chondroprotective refers to preserving cartilage volume, quality, or function, or slowing catabolic processes that degrade cartilage:

• Experimental and clinical data indicate PRP can downregulate catabolic enzymes (e.g., MMP-13, ADAMTS-5) and upregulate anabolic signaling (SOX9, COL2A1) in chondrocytes and mesenchymal cells, tipping the balance toward maintenance of cartilage matrix (Xing et al., 2021).
• Some MRI-based studies suggest reduced rates of cartilage degeneration or improved cartilage quality markers following PRP protocols in early OA. However, the magnitude and durability vary with PRP composition and patient phenotype (Di Martino et al., 2019).
• Not all PRP is equivalent: Leukocyte-poor PRP (LP-PRP) is often favored intra-articularly to minimize neutrophil-driven protease activity and post-injection flares, whereas leukocyte-rich PRP (LR-PRP) may be considered for tendinous or extra-articular indications, given differing inflammatory needs.

In practice, I preferentially use LP-PRP for intra-articular knee OA, aiming for a moderate platelet concentration (typically ~3–5x baseline), as excessive concentrations may paradoxically inhibit cell proliferation or increase inflammatory mediators.

Patient Selection: Who Benefits Most

Careful phenotyping optimizes outcomes:

• Best candidates:

• • Mild-to-moderate OA (Kellgren-Lawrence grade II–III).
  • Mechanical symptoms driven by activity with intermittent swelling.
  • Intact alignment or correctable kinetic chain dysfunctions.
  • Willingness to adhere to rehabilitation and lifestyle

• Caution or alternative strategies:

• • End-stage OA (KL IV) where joint space is near absent; PRP may provide temporary relief but less structural benefit.
  • Severe malalignment (varus/valgus) without bracing or surgical correction consideration.
  • Active infections, coagulopathies, uncontrolled diabetes, or concurrent NSAID overuse inhibiting platelet function.
  • Patients on anticoagulants may need coordination with prescribing clinicians.

The rationale is straightforward: PRP modulates biology, but if mechanical overload remains unchecked—due to malalignment, hip abductor weakness, restricted ankle dorsiflexion, or lumbopelvic dysfunction—the joint continues to experience harmful forces. Hence the necessity of integrative care.

How I Prepare PRP: Details That Determine Outcomes

Quality in, quality out. The biologic profile of PRP depends on the entire workflow:

• Pre-procedure:

• • Avoid NSAIDs for 5–7 days before phlebotomy to preserve platelet responsiveness.
  • Assess comorbidities, medications, and goals; obtain baseline PROMs (e.g., KOOS, WOMAC, NPRS) and functional tests (sit-to-stand, timed up-and-go).

• Collection and processing:

• • Draw peripheral blood into anticoagulated tubes.
  • Use a validated centrifugation protocol to achieve leukocyte-poor plasma with a 3–5x platelet concentration.
  • If possible, verify platelet count to confirm target enrichment.
  • Minimize red blood cell contamination; residual RBCs may increase post-injection irritation.

• Additives:

• • I typically avoid intra-articular exogenous activators; platelets activate upon contact with collagen and synovial factors, providing a more physiologic release of growth factors.

Consistency here increases the probability of reproducible, clinically meaningful responses.

Injection Technique: Why Guidance and Targeting Matter

I perform PRP injections under ultrasound guidance to ensure accurate intra-articular delivery and to tailor adjunct targeting:

• Approach:

• • Anterolateral or superolateral portal depending on effusion and patient habitus.
  • Real-time ultrasound confirms intra-articular spread and avoids neurovascular structures.

• Targeting nuances:

• • For generalized OA, distribute PRP within the suprapatellar recess and across the compartments, then perform gentle knee mobilization afterward.
  • When focal synovitis or meniscal-root pathology is suspected, I target the medial or lateral recess to bathe symptomatic zones.

• Post-injection:

• • Encourage 24–48 hours of relative rest, then initiate graded loading.
  • Avoid NSAIDs for at least 1–2 weeks post-injection; acetaminophen or topical agents can manage transient discomfort.

Ultrasound guidance improves precision and reduces variability—both important for efficacy and safety.

Integrative Chiropractic Care: Correcting the Kinetic Chain

PRP is a biologic catalyst; it works best when the forces across the joint are optimized. This is where integrative chiropractic care is essential:

• Spinal and pelvic alignment:

• • Correcting lumbopelvic dysfunction can normalize femoral internal-rotation moments, thereby reducing medial knee-compartment loading.
  • I frequently address sacroiliac joint asymmetry and thoracolumbar stiffness that alter gait kinetics (Jimenez, n.d.-a).

• Hip mechanics:

• • Restoring hip abductor and external rotator function reduces dynamic valgus.
  • Manual therapy to the iliopsoas, TFL, and gluteal fascia improves force transmission.

• Foot and ankle:

• • Subtalar overpronation or limited ankle dorsiflexion drives compensations at the knee.
  • I employ manipulative therapy, mobilization, and targeted exercises to restore talocrural mechanics and foot tripod stability.

• Myofascial interventions:

• • Instrument-assisted soft tissue mobilization and myofascial release for quadriceps, hamstrings, and calf musculature reduce nociceptive input and improve joint excursion.

• Neuromuscular retraining:

• • Closed-chain drills: sit-to-stand, split squats, step-downs emphasizing knee-over-foot tracking and trunk control.
  • Proprioceptive tasks on variable surfaces for joint position sense.

By aligning joints and retraining movement, we reduce pathologic compressive and shear forces on the knee, allowing PRP’s biochemical effects to translate into durable functional gains.

Exercise Programming and Progressive Loading

Mechanical loading is a medicine for cartilage when dosed correctly:

• Early phase (Week 1–2 after PRP):

• • Emphasize range-of-motion exercises, quad sets, glute bridges, and gentle cycling.
  • Avoid high-impact activities while platelets release growth factors (an initial burst within days, followed by sustained signaling over 1–2 weeks).

• Mid phase (Weeks 3–6):

• • Progress to eccentric quadriceps control (decline squats if tolerated), hip abduction strength, and hamstring eccentrics.
  • Add isometric holds at multiple joint angles to stimulate tendon and periarticular adaptations.

• Late phase (Weeks 6–12):

• • Advance to functional strength (lunges, step-ups with load), agility ladders for athletes, and graded return to running or sport.
  • Integrate rate-of-force development and deceleration mechanics to protect the joint.

Rationale: Cartilage responds to intermittent compressive loading that promotes nutrient diffusion and stimulates chondrocyte anabolism. Progressive loading also conditions periarticular tissues and recalibrates neuromuscular control, reinforcing the benefits of PRP.

Lifestyle Medicine: Anti-Inflammatory Foundations

I coach patients on simple, sustainable behaviors that support joint biology:

• Anti-inflammatory nutrition:

• • Emphasize whole foods, omega-3–rich fish, nuts, colorful vegetables, and polyphenols (e.g., berries, olive oil).
  • Reduce refined carbohydrates and excess omega-6 oils that amplify NF-?B signaling.
  • Consider vitamin D sufficiency and collagen/gelatin plus vitamin C timed before loading to provide amino acids for matrix turnover.

• Weight optimization:

• • Each pound of body weight translates to approximately 4 pounds of compressive force at the knee during gait; modest weight loss yields meaningful reductions in load.

• Sleep and stress:

• • Prioritize 7–9 hours of sleep to optimize growth factor signaling and immune regulation.
  • Incorporate breathwork or mindfulness to lower sympathetic tone, which can dampen central sensitization and pain amplification.

The why: Systemic inflammation and metabolic dysregulation prime the joint for catabolic signaling. Aligning lifestyle inputs with biologic therapy amplifies outcomes.

Safety, Contraindications, and Managing Expectations

PRP is generally safe because it is autologous, reducing immunogenic risks. Key considerations:

• Common, transient effects:

• • Soreness, fullness, or mild swelling for 24–72 hours as part of the desired inflammatory cascade.

• Less common:

• • Post-injection flare or effusion; managed with rest, ice, compression, and short-term acetaminophen.
  • Infection is rare; sterile technique and ultrasound guidance reduce risk.

• Contraindications:

• • Active infection, severe thrombocytopenia, platelet dysfunction syndromes, uncontrolled systemic disease, or inability to pause NSAIDs/anticoagulation as medically appropriate.

I set expectations that benefits often emerge over 2–6 weeks, with continued improvement through 3–6 months. Some patients require a series of 2–3 injections spaced 3–6 weeks apart, depending on symptom burden and goals.

Measuring Outcomes: What We Track and Why

Objective tracking validates progress and guides adjustments:

• Patient-reported outcomes:

• • KOOS and WOMAC to quantify pain, stiffness, function in daily living and sport.
  • NPRS for pain intensity trends.

• Functional metrics:

• • Timed sit-to-stand, gait speed, and stair ascent/descent
  • For athletes: hop tests, change-of-direction, and return-to-play checklists.

• Imaging when appropriate:

• • Baseline and follow-up ultrasound to assess synovitis or effusion.
  • MRI in select cases to evaluate cartilage, bone marrow lesions, or meniscal integrity.

Data-driven care ensures that if a patient plateaus, we can pivot—by adjusting PRP parameters, intensifying kinetic chain correction, or consulting orthopedics when necessary.

Comparing PRP to Steroids and HA: Decision Pathways

Here is how I decide among injectable options:

• Choose PRP when:

• • The patient has mild-to-moderate OA, seeks longer-term improvement, and can engage in rehab.
  • There is a need to address the biologic drivers of OA rather than only symptoms.

• Consider corticosteroids when:

• • Rapid, short-term relief is necessary for an event or acute synovitis flare, and the patient understands the trade-offs.

• Consider hyaluronic acid when:

• • PRP is unavailable or contraindicated, or as an adjunct in patients with viscosupplementation-responsive phenotypes.

By aligning the modality with patient goals and joint biology, we maximize benefit while minimizing risk.

---

Knee Injury Rehabilitation Story- Video

---

Case Patterns From Practice

In my clinical practice, I frequently see these patterns (Jimenez, n.d.-a; Jimenez, n.d.-b):

• The runner with medial knee pain, valgus collapse, and weak hip abductors:

• • After LP-PRP and a focused program on gluteus medius strength, ankle dorsiflexion mobility, and cadence retraining, the patient returns to 10K racing with improved KOOS scores at 12 weeks.

• The active retiree with bilateral knee OA and poor sleep:

• • Combining the LP-PRP series, lumbopelvic adjustments, myofascial release, anti-inflammatory nutrition, and sleep optimization yields sustained functional gains at 6 months and reduced daily use of pain medication.

These illustrate how biologic therapy, biomechanical correction, and lifestyle medicine work synergistically.

Practical Protocol: Bringing It All Together

My integrated protocol for knee OA typically includes:

• Assessment

• • Detailed history, exam, gait analysis.
  • Baseline KOOS/WOMAC/NPRS and functional tests.
  • Consider ultrasound.

• PRP therapy

• • NSAID hold pre- and post-procedure.
  • LP-PRP at 3–5x concentration.
  • Ultrasound-guided intra-articular injection.
  • Reassess at 4–6 weeks; consider 2–3 total injections based on response.

• Chiropractic and rehabilitation

• • Spinal, pelvic, hip, knee, and foot-ankle alignment corrections.
  • Myofascial techniques for the quadriceps, hamstrings, calves, and IT band.
  • Progressive loading: ROM to strength to power and impact.

• Lifestyle medicine

• • Anti-inflammatory nutrition, weight optimization, sleep hygiene, stress modulation.

• Monitoring and iteration

• • Regular PROMs and functional testing.
  • Imaging when indicated.
  • Please adjust the plan based on objective and subjective progress.

The Future of Orthobiologics in Knee OA

The orthobiologic field is rapidly advancing:

• Standardization of PRP composition will improve reproducibility and clarify dose-response relationships.
• Combining PRP with cell-free exosomes or hybrid formulations may further enhance outcomes, pending rigorous trials.
• Better phenotyping—including alignment, inflammation signatures, and activity profiles—will help tailor therapy.

Even as innovation accelerates, the fundamentals remain: match the right biologic to the right patient, correct the mechanics, and train the system to move well.

Key Takeaways

• PRP is a robust, evidence-based option for symptomatic knee osteoarthritis, often outperforming corticosteroids and hyaluronic acid on mid-term outcomes.
• The biologic rationale is strong: PRP modulates inflammation, supports anabolism, and may be chondroprotective in early disease.
• Outcomes are best when PRP is integrated with chiropractic biomechanical correction, progressive rehabilitation, and lifestyle medicine.
• Patient selection, preparation standards (favoring leukocyte-poor), ultrasound guidance, and structured follow-up are critical to success.
• A data-driven, patient-centered approach helps transform symptom relief into lasting function.

For more on how I evaluate and manage musculoskeletal conditions in an integrative practice, you can explore my clinical observations and professional updates on my websites and professional profile (Jimenez, n.d.-a; Jimenez, n.d.-b).

References

• Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., Blanco, F. J., Espinosa, R., Haugen, I. K., Lin, J., Mandl, L. A., Moilanen, E., Nakamura, N., Snyder-Mackler, L., Trojian, T., Underwood, M., & McAlindon, T. E. (2019). OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage, 27(11), 1578–1589.
• Bannuru, R. R., Schmid, C. H., Kent, D. M., Vaysbrot, E. E., Wong, J. B., & McAlindon, T. E. (2015). Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. Annals of Internal Medicine, 162(1), 46–54.
• Bennell, K. L., Paterson, K. L., Metcalf, B. R., Duong, V., Eyles, J. P., Eyles, J. F., & Hinman, R. S. (2021). Platelet-rich plasma injections for knee osteoarthritis: Meta-analyses of randomized controlled trials. Clinical Journal of Sport Medicine, 31(6), e353–e365.
• Di Martino, A., et al. (2019). Platelet-rich plasma versus hyaluronic acid injections for the treatment of knee osteoarthritis: Results at 5 years of a double-blind randomized controlled trial. The American Journal of Sports Medicine, 47(2), 347–354.
• Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., Gellar, K., Harvey, W., Hawker, G., Herzig, E., Kwoh, C. K., Nelson, A. E., Samuels, J., Scanzello, C., White, D., … Reston, J. (2020). 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 72(2), 149–162.
• Xing, D., Kwong, J. S. W., Zang, J., Chen, S., Wang, B., Wang, Y., & Lin, J. (2021). Intra-articular platelet-rich plasma versus hyaluronic acid for knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. The American Journal of Sports Medicine, 49(1), 249–260.
• Jimenez, A. (n.d.-a). Personal Injury Doctor Group.
• Jimenez, A. (n.d.-b). LinkedIn: Dr. Alexander Jimenez.

SEO tags: platelet-rich plasma for knee osteoarthritis, PRP knee OA, PRP vs corticosteroids, PRP vs hyaluronic acid, chondroprotection PRP, integrative chiropractic knee pain, ultrasound-guided PRP injection, leukocyte-poor PRP, evidence-based chiropractic, functional rehabilitation knee OA, anti-inflammatory nutrition osteoarthritis, kinetic chain correction knee, Dr. Alexander Jimenez integrative care, orthobiologics knee osteoarthritis